July 17, 2024

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

April 5, 2024

NGM Bio Announces Closing of Tender Offer

March 19, 2024

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

March 11, 2024

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP

February 20, 2024

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

January 17, 2024

NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 9, 2024

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Contact Information

investor relations

media relations